Skip to content

Narrow Versus Wide Focal Zones for Shock Wave Lithotripsy of Renal Calculi

Multicentred, Randomized Control Trial Comparing Narrow Versus Wide Focal Zones for Shock Wave Lithotripsy of Renal Calculi

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01226875
Enrollment
275
Registered
2010-10-22
Start date
2011-01-31
Completion date
2017-04-30
Last updated
2017-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Stones

Keywords

SWL, kidney stones, renal calculi

Brief summary

Shockwave lithotripsy (SWL) is a safe, non-invasive treatment for renal calculi. During SWL energy is focused on in order to break kidney stones and this energy can be varied in size from a narrow (or small) focal zone to a wide (or large) focal zone. This is a multi-centered, randomized study comparing the single treatment success rates of narrow and wide focal zones during SWL.

Detailed description

Shock wave lithotripsy (SWL) is a safe and non-invasive treatment for kidney stones. The SWL machine that is currently in use has a unique feature: the focal zone or the energy that the SWL energy is focused on in order to break kidney stones can be varied in size from a narrow (or small) focal zone to a wide (or large) focal zone. Previous lithotripters have only offered one focal size that corresponded to a narrow range. The objective of this study is to compare the single-treatment success rates of narrow and wide focal zones for the shock wave lithotripsy of renal stones between 5 and 15 mm in greatest diameter, while maintaining a constant overall lithotripsy energy level. A wide focal zone may offer some trade-offs when compared with the traditional narrow focal zone: since the area being treated is larger, it is more likely that the stone will receive adequate energy as it moves with patient breathing during treatment, and less energy per cubic inch will be delivered to the kidney around the stone (which might lead to a lower degree of renal injury); on the other hand less energy per cubic inch will also be delivered to the stone, so that stone fragmentation might be inferior to that with a narrow focal zone. Thus, with this study we want to determine whether there is a significant difference in both stone fragmentation and in renal injury (as measured by the incidence of post-treatment renal hematoma or bruises, and by measuring urinary markers indicating the degree of renal cellular damage). Aside from the random choice of focal zone size, there will be no change to the standard of care for lithotripsy treatment. We predict that the narrow focal shock zone will result in superior stone fragmentation, with higher single-treatment stone free and success rates. However, we may identify a slight increased incidence in the rate of subcapsular renal hematoma and renal damage, as detected by urinary markers.

Interventions

PROCEDURESWL: Shock Wave Lithotripsy Intervention

Shock wave lithotripsy (SWL) is the most common treatment modality for kidney stones. It is a safe and non-invasive treatment performed on patients under intravenous sedation (light anesthesia) on an out-patient basis, whereby shock waves are generated by a source external to the patient's body and are then propagated into the body and focused on a kidney stone. The unique quality of SWL is in its exploitation of shock wave focusing. The Storz lithotripter is an electromagnetic lithotripter with a unique design that allows for a dual focus system with the option of either a narrow (6x28 mm) or wide (9x50 mm) focal zone, depending on the clinical situation. This is the first lithotripter on the market to allow for two different focal zones for shock wave targeting.

Sponsors

University of Toronto
CollaboratorOTHER
University of Western Ontario, Canada
CollaboratorOTHER
University of British Columbia
CollaboratorOTHER
Unity Health Toronto
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Stone must be radiopaque on a KUB (kidney, ureter and bladder) radiograph, and located within the renal collecting system. * Patients must have had a CT scan within the past 30 days. * Stones must be solitary, between 5 and 15 mm in maximal diameter. * Patient must consent to the trial and be willing to return to their respective lithotripsy unit at 2 weeks and 3 months for follow-up. * Patients must be treated on the Storz Modulith SLX-F2 machine

Exclusion criteria

* More than one renal calculus on the treated side. * Radiolucent stones (uric acid, indinavir) or cystine stones. * Stone size \< 5 mm and \> 15 mm. * Previous surgical intervention on upper tracts within past five years. * Congenital anatomic anomalies of the kidney, ureters or bladder (such as calyceal diverticulum, horseshoe kidney, etc.) * Patient currently taking an α-blocker (alfuzosin, terazosin, doxazosin, tamsulosin, prazosin), calcium channel blocker (verapamil, diltiazem, nifedipine, nicardipine, bepridil, mibefradil), or corticosteroids. * Pregnancy. * Age \< 18 years. * Active urinary tract infection. * Patient exceed weight limit for SWL table (\>500 lbs) * Previous SWL treatment for this stone. * Uncorrected coagulopathy

Design outcomes

Primary

MeasureTime frameDescription
SWL efficiency quotient comparison between narrow focus vs wide focus2 and 12 weeksComparison of single-treatment lithotripsy success rates at 2 and 12 weeks post-lithotripsy. Successful treatment will be defined as either stone-free status or presence of clinically insignificant asymptomatic residual fragments ≤ 4 mm. SWL efficiency quotient for the treatment groups, as calculated by the standardized formula: % stone-free divided by (100 + % re-treated + % auxiliary procedures).

Secondary

MeasureTime frameDescription
Incidence of perirenal hematomaspost treatmentComparing the narrow and wide foci for the presence of perirenal hematomas post treatment on ultrasound.
Biomarkers for renal injuryday 0; day 1; 1 weekComparisons of urinary markers for identifying renal injury
Time to stone passage12 weeksTime it took to pass the stone for both arms will be compared for the 3 month follow up time.
Pain will be compared between narrow vs wide focus armsday 0 (post treatment)Visual analog pain scores will be compared between arms.
Complication rates12 weeksComplication rates will be compared between narrow and wide focus treatment arms.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026